Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer ...Middle East

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™...

Hence then, the article about blueprint medicines announces fda approval of gavreto pralsetinib for the treatment of patients with advanced or metastatic ret mutant and ret fusion positive thyroid cancer was published today ( Tuesday 01/12/2020 - 11:31 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer )

Also on site :

• The C.I.A. Helped Pinpoint a Gathering of Iranian Leaders. Then Israel Struck.
• Former teacher at private school in Calabasas charged with annoying or molesting female students, secretly photographing them
• Wildfire starts near Chautauqua Park in Boulder; dozens of firefighters on scene